Best of ASCO - 2014 Annual Meeting

 

Welcome

HER2-Positive

Breast Cancer—Metastatic

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.

Krystal Pauline Cascetta

TPS1103

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.

Jose Baselga

TPS1102

A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].

Stephen K. L. Chia

1029

A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”.

Niamh M. Keegan

1036

A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).

Romualdo Barroso-Sousa

TPS1100

A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).

Jose Pablo Leone

1026

Ado-trastuzumab emtansine (T-DM1) induced pulmonary toxicity: A retrospective analysis of a single institution experience.

Heidi Egloff

e13004

An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

Jiayu Wang

1030

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

Binghe Xu

1028

Assesment of cardiac effects of ado-trastuzumab emtansine through strain rate imaging in metastatic breast cancer.

Vasiliki Michalaki

e13007

Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial.

Aleksei Manikhas

110

Changes in patient (pt), tumor, and treatment characteristics over time in 1st line (1L) trastuzumab (H) plus taxane (T; paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer (MBC) trials.

Tanja Badovinac Crnjevic

e13024

Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer.

Rashmi Krishna Murthy

1015

Clinical outcome of Russian HER2-positive breast cancer patients with brain metastases: Retrospective review.

L.G. Zhukova

e13025

Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.

Giampaolo Bianchini

e13012

Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry.

Farideh Z. Bischoff

e13019

Effect of breast tumor subtype and site of distant metastatic disease on prognostic outcome among patients with brain metastases and stage IV denovo breast cancer.

Shaheenah S. Dawood

1034

Efficacy and tolerability of first-line anti-HER2 therapy for HER2+ advanced breast cancer: A single-centre real-world experience.

Nicolo Matteo Luca Battisti

e13014

Evaluation of BRCA1, STAT-1 and STAT-3 expression in non familial breast cancer from North India: An interim analysis.

Sameer Gupta

e13010

Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.

Ander Urruticoechea

1013

Fulvestrant efficacy in artificial menopausal hormone receptor positive and HER 2 negative metastatic breast cancer patients under 50 years old.

Caglayan Geredeli

e13000

Genomic testing for HER2 mutation in patients with metastatic lobular carcinoma of the breast.

Dennis L. Citrin

e13022

Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.

Zongbi Yi

1039

Linking pBRD4 and PP2A inhibition in triple negative breast cancer.

Manuel Pedregal

e13011

Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer.

Rui Wang

e13005

Moving from the CLEOPATRA study to real life: Results from the G.O.N.O. SUPER trial.

Ornella Garrone

e13006

Neglected breast cancer in the Appalachians.

Ruta Arays

e13023

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).

Jame Abraham

1027

PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.

Tomás Pascual

1025

Phase I results of CAM-H2: Safety profile and tumor targeting in patients.

Marleen Keyaerts

e13017

Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results.

Tejal Amar Patel

1035

Phase II clinical trial of the 1st line combination therapy of eribulin and trastuzumab for advanced or recurrent HER2-positive breast cancer.

Koichi Sakaguchi

e13016

Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.

Neil Conlon

e13021

Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.

Ran Ran

e13018

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets).

Ashwini Shewade

1037

Relationship of healthcare costs and disease progression in patients with HER2+ breast cancer.

Hans-Peter Goertz

e13013

Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.

Erika Paige Hamilton

1032

Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.

Ji-Yeon Kim

e13009

SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.

Filipa Lynce

1038

Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).

David B. Page

1033

Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).

Kim Leitzel

1031

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.

Patricia Villagrasa

TPS1101